Franziska Severin1, Björn Stollenwerk1, Elke Holinski-Feder2, Elisabeth Meyer1, Volker Heinemann3, Clemens Giessen-Jung3, Wolf Rogowski1. 1. Institute for Health Economics and Health Care Management, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany. 2. Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Munich, Germany. 3. Department of Medical Oncology and Comprehensive Cancer Center, Ludwig-Maximilians-Universität München, Munich, Germany.
Abstract
PURPOSE: Lynch syndrome (LS) screening among patients with newly diagnosed colorectal cancer can decrease mortality in their affected first-degree relatives. In Germany, it is not yet clinical practice and the cost-effectiveness of different testing strategies is unknown. METHODS: We developed a decision-analytic model to analyze the cost-effectiveness of LS screening from the perspective of the German Statutory Health Insurance system. A total of 22 testing strategies considering family-history assessment, analysis of tumor samples (i.e., immunohistochemistry (IHC), microsatellite instability, and BRAF mutation testing) and genetic sequencing were analyzed. Life-years gained in relatives by closed-meshed colonoscopy and aspirin prophylaxis were estimated by Markov models. Uncertainty was assessed deterministically and probabilistically. RESULTS: On average, detected mutation carriers gained 0.52 life-years (undiscounted: 1.34) by increased prevention. Most strategies were dominated, with three exceptions: family assessment by the Bethesda criteria followed by IHC and BRAF testing and genetic sequencing; IHC and BRAF testing and genetic sequencing; and direct sequencing of all index patients. Their incremental cost-effectiveness was [euro ]77,268, [euro ]253,258, and [euro ]4,188,036 per life-year gained, respectively. CONCLUSION: The results were less favorable than those of previous models. Chemoprevention appears to provide comparably low additional benefit and improves cost-effectiveness only slightly.
PURPOSE: Lynch syndrome (LS) screening among patients with newly diagnosed colorectal cancer can decrease mortality in their affected first-degree relatives. In Germany, it is not yet clinical practice and the cost-effectiveness of different testing strategies is unknown. METHODS: We developed a decision-analytic model to analyze the cost-effectiveness of LS screening from the perspective of the German Statutory Health Insurance system. A total of 22 testing strategies considering family-history assessment, analysis of tumor samples (i.e., immunohistochemistry (IHC), microsatellite instability, and BRAF mutation testing) and genetic sequencing were analyzed. Life-years gained in relatives by closed-meshed colonoscopy and aspirin prophylaxis were estimated by Markov models. Uncertainty was assessed deterministically and probabilistically. RESULTS: On average, detected mutation carriers gained 0.52 life-years (undiscounted: 1.34) by increased prevention. Most strategies were dominated, with three exceptions: family assessment by the Bethesda criteria followed by IHC and BRAF testing and genetic sequencing; IHC and BRAF testing and genetic sequencing; and direct sequencing of all index patients. Their incremental cost-effectiveness was [euro ]77,268, [euro ]253,258, and [euro ]4,188,036 per life-year gained, respectively. CONCLUSION: The results were less favorable than those of previous models. Chemoprevention appears to provide comparably low additional benefit and improves cost-effectiveness only slightly.
Authors: H T Lynch; P Watson; T G Shaw; J F Lynch; A E Harty; B A Franklin; C R Kapler; S T Tinley; B Liu; C Lerman Journal: Cancer Date: 1999-12-01 Impact factor: 6.860
Authors: Roland P Kuiper; Lisenka E L M Vissers; Ramprasath Venkatachalam; Danielle Bodmer; Eveline Hoenselaar; Monique Goossens; Aline Haufe; Eveline Kamping; Renée C Niessen; Frans B L Hogervorst; Johan J P Gille; Bert Redeker; Carli M J Tops; Marielle E van Gijn; Ans M W van den Ouweland; Nils Rahner; Verena Steinke; Philip Kahl; Elke Holinski-Feder; Monika Morak; Matthias Kloor; Susanne Stemmler; Beate Betz; Pierre Hutter; David J Bunyan; Sapna Syngal; Julie O Culver; Tracy Graham; Tsun L Chan; Iris D Nagtegaal; J Han J M van Krieken; Hans K Schackert; Nicoline Hoogerbrugge; Ad Geurts van Kessel; Marjolijn J L Ligtenberg Journal: Hum Mutat Date: 2011-03-01 Impact factor: 4.878
Authors: Tuan A Dinh; Benjamin I Rosner; James C Atwood; C Richard Boland; Sapna Syngal; Hans F A Vasen; Stephen B Gruber; Randall W Burt Journal: Cancer Prev Res (Phila) Date: 2010-11-18
Authors: Yen Y Tan; Julie McGaughran; Kaltin Ferguson; Michael D Walsh; Daniel D Buchanan; Joanne P Young; Penelope M Webb; Andreas Obermair; Amanda B Spurdle Journal: Int J Cancer Date: 2013-01-11 Impact factor: 7.396
Authors: Bernard F Cole; Richard F Logan; Susan Halabi; Robert Benamouzig; Robert S Sandler; Matthew J Grainge; Stanislas Chaussade; John A Baron Journal: J Natl Cancer Inst Date: 2009-02-10 Impact factor: 13.506
Authors: John Burn; Anne-Marie Gerdes; Finlay Macrae; Jukka-Pekka Mecklin; Gabriela Moeslein; Sylviane Olschwang; Diane Eccles; D Gareth Evans; Eamonn R Maher; Lucio Bertario; Marie-Luise Bisgaard; Malcolm G Dunlop; Judy W C Ho; Shirley V Hodgson; Annika Lindblom; Jan Lubinski; Patrick J Morrison; Victoria Murday; Raj Ramesar; Lucy Side; Rodney J Scott; Huw J W Thomas; Hans F Vasen; Gail Barker; Gillian Crawford; Faye Elliott; Mohammad Movahedi; Kirsi Pylvanainen; Juul T Wijnen; Riccardo Fodde; Henry T Lynch; John C Mathers; D Timothy Bishop Journal: Lancet Date: 2011-10-27 Impact factor: 79.321
Authors: Karl Johnson; Katherine W Saylor; Isabella Guynn; Karen Hicklin; Jonathan S Berg; Kristen Hassmiller Lich Journal: Genet Med Date: 2021-12-07 Impact factor: 8.822
Authors: Elisabeth F P Peterse; Steffie K Naber; Corinne Daly; Aaron Pollett; Lawrence F Paszat; Manon C W Spaander; Melyssa Aronson; Robert Gryfe; Linda Rabeneck; Iris Lansdorp-Vogelaar; Nancy N Baxter Journal: Clin Gastroenterol Hepatol Date: 2019-10-17 Impact factor: 11.382
Authors: Celine H M Leenen; Anne Goverde; Esther W de Bekker-Grob; Anja Wagner; Margot G F van Lier; Manon C W Spaander; Marco J Bruno; Carli M Tops; Ans M W van den Ouweland; Hendrikus J Dubbink; Ernst J Kuipers; Winand N M Dinjens; Monique E van Leerdam; Ewout W Steyerberg Journal: Genet Med Date: 2016-03-03 Impact factor: 8.822